               SEQUENCE LISTING

<110> Domain Therapeutics

<120> Novel PAR-2 inhibitors

<130> AD1622 PCT

<150> EP20 30 6495.1
<151> 2020-12-03

<160> 3

<170> BiSSAP 1.3.6

<210> 1
<211> 6
<212> PRT
<213> Artificial Sequence


<220> 
<223> 2-Furoyl-LIGRLO-NH2 peptide

<220> 
<221> VARIANT
<222> 1
<223> Leu = N-(2-Furoyl)-Leu

<220> 
<221> MOD_RES
<222> 6
<223> AMIDATION

<220> 
<221> VARIANT
<222> 6
<223> Xaa = Ornithine

<400> 1
Leu Ile Gly Arg Leu Xaa 
1               5       

<210> 2
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> synthetic peptide comprising tethered ligand

<400> 2
Arg Ser Leu Ile Gly Lys Val 
1               5           

<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence


<220> 
<223> tethered ligand

<400> 3
Ser Leu Ile Gly Lys Val 
1               5       

